Milatuzumab: Difference between revisions

{{Short description|Monoclonal antibody}}

| Watchedfields = changed

| verifiedrevid = 458284030

| image =

<!-- Monoclonal antibody data -->

<!-- Clinical data -->

| tradename =

| pregnancy_category =

| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->

| legal_status =

| routes_of_administration =

<!-- Pharmacokinetic data -->

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

<!-- Identifiers -->

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 899796-83-9

| ATC_suffix =

| PubChem =

| DrugBank =

| ChemSpiderID = none

<!-- Chemical data -->

| C=6518 | H=10066 | N=1758 | O=2020 | S=40

'''Milatuzumab''' (or '''hLL1''') is an anti-CD74<ref name="pmid17875789">{{cite journal | vauthors = Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM | display-authors = 6 | title = CD74: a new candidate target for the immunotherapy of B-cell neoplasms | journal = Clinical Cancer Research | volume = 13 | issue = 18 Pt 2 | pages = 5556s–5563s | date = September 2007 | pmid = 17875789 | doi = 10.1158/1078-0432.CCR-07-1167 | s2cid = 23818626 }}</ref> humanized [[monoclonal antibody]] for the treatment of [[multiple myeloma]] non-Hodgkin's lymphoma and chronic lymphocytic leukemia.<ref name="pmid21228331">{{cite journal | vauthors = Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA | display-authors = 6 | title = Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma | journal = Blood | volume = 117 | issue = 17 | pages = 4530–4541 | date = April 2011 | pmid = 21228331 | pmc = 3099572 | doi = 10.1182/blood-2010-08-303354 }}</ref><ref name="Berkova_2010">{{cite journal | vauthors = Berkova Z, Tao RH, Samaniego F | title = Milatuzumab - a promising new immunotherapeutic agent | journal = Expert Opinion on Investigational Drugs | volume = 19 | issue = 1 | pages = 141–9 | date = January 2010 | pmid = 19968579 | doi = 10.1517/13543780903463854 | s2cid = 207475327 }}</ref>

The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of [[multiple myeloma]]. Milatuzumab has received [[orphan drug]] designation from the Food and Drug Administration in the United States for the treatment of [[multiple myeloma]] and [[chronic lymphocytic leukemia]].

Milatuzumab was developed by [http://www.immunomedics.com Immunomedics, Inc], (Morris Plains NJ USA).

==CD74==

{{Contradicts other|date=November 2015|1=CD74}}

{{Refimprove section|date=November 2015}}

[[CD74]] is present on a variety of hematological tumors and even on some solid cancers. It is present in limited amounts in normal tissues but widely found in leukemias, lymphomas and the vast majority of multiple myeloma cases.{{cn|date=November 2015}} CD74 is involved in a cell-to-cell communication pathway that is critical for survival.{{cn|date=November 2015}} When CD74 is blocked by milatuzumab, it can lead to cell death.

CD74 is an attractive target for a drug conjugate because of its rapid internalizing property.{{cn|date=November 2015}}

In preclinical studies with human lymphomas and myelomas, both naked Milatuzumab and the Milatuzumab conjugated with doxorubicin,<ref>Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. P. Sapra, R. Stein, J. Pickett, Z. Qu, S.V. Govindan, T.M. Cardillo, H.J. Hansen, I.D. Horak, G.L. Griffiths, D.M. Goldenberg. Clin Cancer Res 11:5257-5264, 2005.</ref> an [[antibody-drug conjugate]] or ADC, have demonstrated anti-lymphoma activity ''in-vivo.''

==Antibody-drug Conjugates==

===IMMU-110===

;hLL1-Dox: Milatuzumab has been linked to [[doxorubicin]] to form an [[antibody-drug conjugate]] or ADC (known as hLL1-Dox or IMMU-110) for treatment of relapsed [[multiple myeloma]]. A Phase I/II clinical trial to evaluate this milatuzumab-doxorubicin conjugate began in 2010,<ref>{{cite web | title = Milatuzumab-Doxorubicin (IMMU-110 / hLL1-dox) Clinical Trials | work = ADC Review / Journal of Antibody-drug Conjugates | url = http://adcreview.com/multiple-myeloma-immu-110-clinical-trials/ }}</ref><ref>{{cite web | url = http://www.news-medical.net/news/20100616/Immunomedics-initiates-dosing-in-milatuzumab-doxorubicin-conjugate-Phase-III-trial-for-relapsed-multiple-myeloma.aspx | title = Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma | work = News Medical and Immunomedics Press Release |date=16 June 2010 }}</ref> but was terminated in 2021 due to lack of efficacy.<ref>{{ClinicalTrialsGov|NCT01101594|A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma}}</ref>

{{Reflist}}

[[Category:Monoclonal antibodies]]

[[Category:Experimental cancer drugs]]